Pharmafile Logo
Pharmafocus logo
Advanced Search

Dupixent

Showing 10 posts of 25 posts found.

dw-anzcxqaqavhl

FDA approves Dupixent for chronic rhinosinusitis with nasal polyposis

June 27, 2019
Sales and Marketing Dupixent, FDA, Sanofi, US, pharma, rhinosinusitis

Regeneron Pharmaceuticals and Sanofi have revealed that their dual IL-4 and IL-13 inhibitor Dupixent (dupilumab) has secured FDA approval in …

News
dupixentpackage

Sanofi’s Dupixent approved in Europe for severe asthma maintenance

May 9, 2019
Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma

Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …

News
dupixentpackage

FDA expands Dupixent indication to include moderate-to-severe atopic dermatitis in adolescent patients

March 12, 2019
Manufacturing and Production, Sales and Marketing Dupixent, Regeneron, Sanofi, pharma

Partners Sanofi and Regeneron have both revealed that their jointly developed drug Dupixent (dupilumab) has been authorised by the FDA …

News

Sanofi’s Dupixent improves symptoms in rhinosinusitis with nasal polyps at Phase 3

February 27, 2019
Research and Development Dupixent, Sanofi, pharma, rhinosinusitis

New data has been released on Sanofi’s Dupixent (dupilumab), derived from two Phase 3 trials, illustrating the drug’s efficacy In …

News

Sanofi’s Dupixent improves symptoms for adolescent atopic dermatitis patients

September 17, 2018
Research and Development, Sales and Marketing Dupixent, EADV 2018, Sanofi, atopic dermatitis, pharma

Sanofi’s Dupixent (dupilumab) has made a strong showing as a monotherapy at Phase 3 in the treatment of moderate-to-severe atopic …

News

NICE rejects Dupixent for atopic dermatitis on cost grounds, Sanofi responds

April 4, 2018
Research and Development, Sales and Marketing Dupixent, NICE, Sanofi, atopic dermatitis, eczema, pharma

UK drug watchdog NCIE has issued draft guidance rejecting the routine use of Sanofi’s Dupixent (dupilumab) for the treatment of …

News
sanofi_regeneron

Sanofi and Regeneron’s projected blockbuster gains EU approval

September 28, 2017
Sales and Marketing Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron have big hopes for their treatment Dupixent, and it has taken an important step towards reaching the …

News
sanofi_regeneron

Sanofi/Regeneron new asthma data bolstered by potential indications

September 13, 2017
Research and Development Dupixent, Regeneron, Sanofi, biotech, drugs, pharma, pharmaceutical

Sanofi and Regeneron’s Dupixent is predicted to grow to be one of the largest selling drugs in the industry but …

News

FDA approves first-ever atopic dermatitis biologic treatment

March 31, 2017
Medical Communications, Sales and Marketing Dupixent, Regeneron, Sanofi, atopic dermatitis, biologic

Sanofi and Regeneron’s Dupixent (dupilumab) has become the first biologic medicine to be approved by the FDA for the treatment …

News
sanofi_regeneron

Breakthrough eczema drug given FDA approval

March 29, 2017
Research and Development, Sales and Marketing Dupixent, Regeneron, Sanofi

Regeneron and Sanofi have received approval for its eczema treatment, Dupixent, by the FDA. The treatment will be the first …

News
The Gateway to Local Adoption Series

Latest content

Five Facts about the menopause

March 6, 2026

Zello Appoints Kevin Bailey as Group Chief Medical Officer

March 6, 2026

BioDuro establishes joint manufacturing venture with Cenra

March 6, 2026

Symbiosis appoints Joanne Anderson as Chief Commercial Officer

March 6, 2026

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

March 6, 2026